By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lakewood-Amedex Inc. 

7004 Stanhope Place

University Park  Florida  34201  U.S.A.
Phone: 941-359-0510 Fax: 941-359-9425


Company News
Lakewood-Amedex Inc. Completes Clinical Trial Recruitment For Final Cohort Of The Company's Phase I/IIa Program In Patients With Infected Diabetic Foot Ulcers 8/23/2017 6:20:38 AM
Lakewood-Amedex Inc. Advances Novel Bisphosphocin Nu-8 Compound Based On Encouraging Pre-Clinical Results 4/4/2017 9:47:49 AM
Lakewood-Amedex Inc. Appoints Chief Medical Officer And Chief Scientific Officer To Enhance Drug Development And Clinical Trials Programs 5/26/2016 9:17:25 AM
Lakewood-Amedex Inc. Announces Its Novel Bisphospocin Class Of Antimicrobials Kills Multidrug Resistant-Tuberculosis (MDR-TB) Strains In Fifteen Minutes 5/19/2015 10:59:47 AM
Lakewood-Amedex Inc. Announces Expanded Research Collaboration With The University Of Jyvaskyla Following Promising Results Demonstrating Bisphosphocin Activity Against Borrelia Burgdorferi 3/12/2015 10:05:47 AM
Lakewood-Amedex Inc. Submits Investigational New Drug Application For Bisphosphocin Nu-3 For The Treatment Of Diabetic Foot Infections 12/11/2014 8:37:11 AM
Lakewood-Amedex Inc. Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 9/11/2014 9:09:13 AM
Lakewood-Amedex Inc. Raises $5.5 Million In Series C Preferred Stock Financing 6/18/2014 9:53:31 AM
Lakewood-Amedex Inc. Signs Strategic Advisory Agreement With H.C. Wainwright & Co. 10/9/2013 8:50:26 AM
Lakewood-Amedex Inc. to Present Data on Bisphosphocin™ Nu-3 Bacteriacidal Effect on Bacteria Established in Biofilm at the ICAAC Conference 9/11/2013 6:26:50 AM